Tebentafusp not checked

Immunocore Ltd · IMCgp100

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
5 active
8 in total · 5 in the EU
Targets
 

What this is

How it works
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager FDA class
How it’s given
“Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab”In the company’s words, NCT05549297 on ClinicalTrials.gov
Tested for
Advanced Melanoma, Select Advanced Solid Tumors
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.”In the company’s words, NCT05549297 on ClinicalTrials.gov
Other names
IMCgp100 · Kimmtrak

Other drugs for Advanced Melanoma

All 196 drugs for Advanced Melanoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Mar 2028 Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 1/2Active, not recruiting Oct 2026 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Phase 2Completed 13 Oct 2020 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Phase 1/2Completed 20 Mar 2020 A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Phase 1/2Withdrawn 19 Jun 2023 Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Phase 2Authorised not given Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma
Phase 3Authorised not given EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial)
Phase 2Authorised not given Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tebentafusp

Following is part of Solo: you see every change to Tebentafusp the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in